SYNAPSE Blend for Men: What the Research Has Looked At, and What to Check First

The first phase 3 trial, in the New England Journal of Medicine in 2007, randomised 412 people with HIV and abdominal fat accumulation, 86 percent men, to tesamorelin 2 mg daily or placebo for 26 weeks. Visceral fat on CT fell 15.2 percent on treatment and rose 5.0 percent on placebo, and IGF-1 rose 81 percent. A pooled analysis with a second trial covered 806 patients. Every trial that measured it found no significant change in the fat under the skin.

For men. These trials describe men more than women because of who enrolled, but they describe HIV-associated fat redistribution at 2 mg daily, four times the tesamorelin in a SYNAPSE dose. One 2012 trial of 60 abdominally obese adults with reduced growth hormone secretion reported the same selective effect outside HIV. None of it is a trial of SYNAPSE, and none measured weight or appearance. More in tesamorelin for men.

A 2021 paper in Aging looked at an East Asian mitochondrial DNA variant that changes one amino acid in MOTS-c. Across three cohorts totalling 27,527 people, the variant was associated with a higher prevalence of type 2 diabetes in men, particularly sedentary men, and in mice and cells the variant peptide lost its insulin-sensitising activity. That is what a natural variant correlates with, not what an injection does. There are no randomised trials of MOTS-c in people of either sex. More in MOTS-c for men.

Semax's human evidence is Russian clinical work in stroke and cerebrovascular disease using a nasal product, plus a 14-person brain-imaging study; the one male-specific study in the live research is a 2024 experiment in male rats under chronic stress. Selank's human evidence is a set of small Russian trials in patients with anxiety disorders, compared with benzodiazepines. Neither reports separate results for men, and neither tested the subcutaneous route. See Semax for men and Selank for men.

The reason tesamorelin sits in a blend with this name is a 2012 Archives of Neurology trial: 152 adults aged 55 to 87, tesamorelin 1 mg or placebo at bedtime for 20 weeks, with a favourable effect on a cognitive composite driven mainly by executive function. It was tesamorelin alone, in older adults, at twice the SYNAPSE dose, and the authors called for longer trials. It is not evidence about this blend or about younger men.

No component of SYNAPSE is described as acting on testosterone. Tesamorelin acts on the growth hormone axis, MOTS-c on a cellular energy pathway, and Semax and Selank on brain signalling; none is a steroid or anabolic agent. Low drive, poor focus and a softening waist can point at genuinely low testosterone, which is a different treatment with its own monitoring. See peptides for testosterone.

Tesamorelin's approved label states it is not indicated for weight-loss management because its effect on weight is neutral, and MOTS-c has no human trials. Where weight itself is the problem, the GLP-1 medications have the trial evidence. If body composition is the whole goal and focus is not, FUSION and PHYSIQ carry tesamorelin and MOTS-c without the neuropeptides.

No study has looked at SYNAPSE or any component with testosterone replacement, and no interaction list exists. Tesamorelin and testosterone move overlapping markers: IGF-1 is tracked on the growth hormone side, and testosterone can raise IGF-1 too. Glucose is the marker they pull on in opposite directions. List your testosterone prescription, your dose and whoever manages it on your intake. More in can you take peptides with testosterone.

A mouse study cited in the FDA's Semax briefing reported Semax potentiating amphetamine-induced dopamine release. No equivalent human finding exists. If you take a stimulant, including prescription ADHD medication, your physician needs to know before starting, and SYNAPSE is not a substitute for that treatment.

Growth hormone reduces insulin sensitivity, and the approved tesamorelin label records new-onset diabetes in 5% of treated patients against 1% on placebo at 2 mg daily. MOTS-c is described in mice improving insulin sensitivity. Nobody has measured the two together. Diabetes, prediabetes or a borderline fasting glucose belongs on the intake, and thirst or frequent urination is a reason to message your care team.

Tesamorelin raises growth hormone and IGF-1. The approved product is contraindicated in active malignancy, requires any prior malignancy to be inactive with treatment complete, and states that the effects of prolonged IGF-1 elevation are unknown. A personal or family history of prostate or any other cancer goes on the intake in full. See can peptides cause cancer.

No study in the live research has looked at any SYNAPSE component and male fertility, so the effect is unknown rather than shown to be nil. If conception is a goal, raise it with your physician before starting. See do peptides affect fertility.

The 2026 WADA Prohibited List names tesamorelin under S2.2.4 and MOTS-c under S4.4.1, both prohibited at all times, in and out of competition. USADA has stated MOTS-c is not eligible for a therapeutic use exemption. A prescription does not change that, and the small amount in a blend does not matter. See is SYNAPSE blend banned in sports.